Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL-0951 (Enarodustat) Phase 3 in Non-dialysis CKD Anemia
NCT06016036Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enarodustat in anemia of chronic kidney disease (CKD-A), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
enarodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT06016036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016036.